RT Journal Article
SR Electronic
T1 Rapid and Quantitative Detection of Human Antibodies Against the 2019 Novel Coronavirus SARS CoV2 and its Variants as a Result of Vaccination and Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.13.21260442
DO 10.1101/2021.07.13.21260442
A1 Taubner, Benjamin
A1 Peredo-Wende, Ruben
A1 Ramani, Ananthakrishnan
A1 Singh, Gurpreet
A1 Strle, Klemen
A1 Cady, Nathaniel C.
YR 2021
UL http://medrxiv.org/content/early/2021/07/16/2021.07.13.21260442.abstract
AB Measuring the antibody response to 2019 SARS CoV2 is critical for diagnostic purposes, monitoring the prevalence of infection, and for gauging the efficacy of the worldwide vaccination effort COVID-19. In this study, a microchip-based grating coupled fluorescent plasmonic (GC-FP) assay was used to measure antibody levels that resulted from COVID-19 infection and vaccination. In addition, we measured the relative antibody binding towards antigens from variants CoV2 virus variants, strains B.1.1.7 (UK) and B.1.351 (S. African). Antibody levels against multiple antigens within the SARS CoV2 spike protein were significantly elevated for both vaccinated and infected individuals, while those against the nucleocapsid (N) protein were only elevated for infected individuals. GC-FP was effective for monitoring the IgG-based serological response to vaccination throughout the vaccination sequence, and could also resolve acute (within hours) increases in antibody levels. A significant decrease in antibody binding to antigens from the B.1.351 variant, but not B.1.1.7, was observed for all vaccinated subjects when measured by GC-FP as compared to the 2019 SARS CoV2 antigens. These results were corroborated by competitive ELISA assay. Collectively, the findings suggest that GC-FP is a viable, rapid, and accurate method for measuring both overall antibody levels to CoV2 and relative antibody binding to viral variants during infection or vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by funding through the State University of New York (SUNY).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Serum samples were collected from COVID-19 patients admitted to Albany Medical Center between October and December 2020 who enrolled in a study Defining genetic and immune factors in COVID-19 severity. All patients had a positive RT-PCR test for CoV2 and were hospitalized due to severity of their illness. Sera were processed on the day of collection and placed into -80C freezer until analyses. The study was approved by the IRB at Albany Medical Center (Protocol # 5929). Dried blood samples were collected by the finger stick method. Lancet devices (27 ga.) and Whatman 903 protein saver collection cards were sent to volunteers with instructions and consent form approved by the SUNY Polytechnic Institute Institutional Review Board (protocol #IRB-2020-10 and #IRB-2021-2).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request.